Literature DB >> 17353252

In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.

Gwan-Han Shen1, Bo-Da Wu, Kun-Ming Wu, Jiann-Hwa Chen.   

Abstract

The in vitro activities of isepamicin against 117 Mycobacteria abscessus, 48 Mycobacterium fortuitum, and 20 Mycobacterium chelonae isolates were evaluated by a microdilution test. Isepamicin MIC(90)s were < or =16 microg/ml for the three species. Isepamicin was as active as amikacin and kanamycin and more active than tobramycin, capreomycin, gentamicin, and streptomycin.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17353252      PMCID： PMC1855558          DOI： 10.1128/AAC.01551-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1997-08       Impact factor: 21.405

Review 2.  Clinical pharmacokinetics and pharmacodynamics of isepamicin.

Authors:  M Tod; C Padoin; O Petitjean
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

3.  In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan.

Authors:  Nai-Cheng Cheng; Po-Ren Hsueh; Yung-Ching Liu; Jainn-Ming Shyr; Wen-Kuei Huang; Lee-Jene Teng; Cheng-Yi Liu
Journal:  Microb Drug Resist       Date:  2005       Impact factor: 3.431

4.  Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis.

Authors:  A Telenti; F Marchesi; M Balz; F Bally; E C Böttger; T Bodmer
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

5.  Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications.

Authors:  S. Kondo; Kunimoto Hotta
Journal:  J Infect Chemother       Date:  1999-03       Impact factor: 2.211

6.  Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.

Authors:  G L Woods; J S Bergmann; F G Witebsky; G A Fahle; A Wanger; B Boulet; M Plaunt; B A Brown; R J Wallace
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

7.  In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria.

Authors:  Y I Ho; C Y Chan; A F Cheng
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

8.  An overview of the safety of isepamicin in adults.

Authors:  D Blum
Journal:  J Chemother       Date:  1995-06       Impact factor: 1.714

9.  Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei.

Authors:  J R Dalovisio; G A Pankey; R J Wallace; D B Jones
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

10.  Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.

Authors:  R J Wallace; J M Swenson; V A Silcox; M G Bullen
Journal:  J Infect Dis       Date:  1985-09       Impact factor: 5.226
View more
  3 in total

1.  Mycobacterium abscessus drug discovery using machine learning.

Authors:  Alan A Schmalstig; Kimberley M Zorn; Sebastian Murcia; Andrew Robinson; Svetlana Savina; Elena Komarova; Vadim Makarov; Miriam Braunstein; Sean Ekins
Journal:  Tuberculosis (Edinb)       Date:  2022-01-20       Impact factor: 3.131

2.  Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases.

Authors:  Toshiyuki Harada; Yasushi Akiyama; Atsuyuki Kurashima; Hideaki Nagai; Kazunari Tsuyuguchi; Takashi Fujii; Syuichi Yano; Eriko Shigeto; Toshihiko Kuraoka; Akira Kajiki; Yoshihiro Kobashi; Fumio Kokubu; Atsuo Sato; Shiomi Yoshida; Tomotada Iwamoto; Hajime Saito
Journal:  J Clin Microbiol       Date:  2012-08-22       Impact factor: 5.948

3.  Antimicrobial susceptibility of standard strains of nontuberculous mycobacteria by microplate Alamar Blue assay.

Authors:  Guilian Li; Lu-Lu Lian; Li Wan; Jingrui Zhang; Xiuqin Zhao; Yi Jiang; Li-Li Zhao; Haican Liu; Kanglin Wan
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.